PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/MTOR INHIBITOR GDC-0084 GIVEN TO GLIOBLASTOMA (GBM) PATIENTS WITH UNMETHYLATED O-6-METHYLGUANINE-METHYLTRANSFERASE (MGMT) PROMOTER STATUS-MedSci.cn

PHASE 2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND CLINICAL ACTIVITY OF PI3K/MTOR INHIBITOR GDC-0084 GIVEN TO GLIOBLASTOMA (GBM) PATIENTS WITH UNMETHYLATED O-6-METHYLGUANINE-METHYLTRANSFERASE (MGMT) PROMOTER STATUS

Wen, PY; de Groot, J; Battiste, JD; Goldlust, SA; Garner, J; Simpson, J; Olivero, A; Cloughesy, T

NEURO-ONCOLOGY, 2019; 21 (): 35

科室
- - 订阅+
  - 更多科室
工具
服务